X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1040) 1040
fludarabine (949) 949
index medicus (789) 789
hematology (726) 726
oncology (670) 670
male (603) 603
female (595) 595
middle aged (530) 530
rituximab (502) 502
cyclophosphamide (486) 486
aged (483) 483
leukemia, lymphocytic, chronic, b-cell - drug therapy (433) 433
adult (429) 429
antineoplastic combined chemotherapy protocols - therapeutic use (378) 378
chronic lymphocytic leukemia (370) 370
treatment outcome (360) 360
vidarabine - analogs & derivatives (357) 357
therapy (288) 288
fludarabine plus cyclophosphamide (266) 266
cancer (264) 264
chemotherapy (262) 262
transplantation (237) 237
care and treatment (233) 233
chronic lymphocytic-leukemia (225) 225
aged, 80 and over (217) 217
leukemia (213) 213
vidarabine - administration & dosage (213) 213
antineoplastic agents - therapeutic use (204) 204
cll (194) 194
prognosis (182) 182
cyclophosphamide - administration & dosage (176) 176
survival (164) 164
antineoplastic combined chemotherapy protocols - adverse effects (159) 159
disease-free survival (157) 157
leukemia, lymphocytic, chronic, b-cell - pathology (155) 155
stem-cell transplantation (154) 154
research (152) 152
chlorambucil (146) 146
leukemia, lymphocytic, chronic, b-cell - mortality (145) 145
alemtuzumab (142) 142
trial (142) 142
previously untreated patients (138) 138
stem cells (135) 135
bone-marrow-transplantation (132) 132
initial therapy (132) 132
non-hodgkins-lymphoma (131) 131
leukemia, lymphocytic, chronic, b-cell - therapy (126) 126
immunology (124) 124
hematology, oncology and palliative medicine (123) 123
health aspects (122) 122
survival analysis (122) 122
vidarabine - therapeutic use (121) 121
medicine & public health (120) 120
retrospective studies (120) 120
phase-ii trial (117) 117
antibodies, monoclonal - therapeutic use (116) 116
hematopoietic stem cells (115) 115
chemoimmunotherapy (114) 114
open-label (114) 114
adolescent (112) 112
lymphoma (112) 112
risk factors (111) 111
drug therapy (110) 110
analysis (107) 107
transplantation conditioning - methods (107) 107
leukemia, lymphocytic, chronic, b-cell - genetics (104) 104
survival rate (104) 104
antineoplastic agents (103) 103
remission induction (102) 102
antimitotic agents (99) 99
patients (98) 98
recurrence (98) 98
antineoplastic combined chemotherapy protocols - administration & dosage (96) 96
leukemia, lymphocytic, chronic, b-cell - diagnosis (95) 95
immunotherapy (94) 94
lymphomas (94) 94
stem cell transplantation (94) 94
diagnosis (93) 93
1st-line therapy (92) 92
combination (91) 91
follow-up studies (91) 91
transplantation, homologous (89) 89
dosage and administration (87) 87
follicular lymphoma (86) 86
hematopoietic stem cell transplantation - methods (86) 86
vidarabine - adverse effects (85) 85
antibodies, monoclonal - administration & dosage (84) 84
pharmacology & pharmacy (84) 84
chronic lymphatic leukemia (83) 83
chronic lymphocytic leukaemia (83) 83
hemic and lymphatic diseases (83) 83
progression-free survival (81) 81
neoplasm staging (79) 79
regimen (79) 79
toxicity (79) 79
hematopoietic stem cell transplantation (78) 78
antibodies, monoclonal, murine-derived (77) 77
article (77) 77
minimal residual disease (77) 77
monoclonal antibodies (77) 77
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1284) 1284
German (6) 6
French (5) 5
Spanish (5) 5
Polish (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9583, pp. 230 - 239
Journal Article
Cancer, ISSN 0008-543X, 01/2012, Volume 118, Issue 2, pp. 434 - 443
Journal Article
Haematologica, ISSN 0390-6078, 2015, Volume 100, Issue 12, pp. e501 - e504
Journal Article
Blood, ISSN 0006-4971, 07/2006, Volume 108, Issue 2, pp. 473 - 479
Journal Article
Pathology oncology research : POR, ISSN 1219-4956, 02/2019, pp. 1 - 10
Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some... 
Pharmacodynamics | Chronic lymphatic leukemia | Leukemia | p53 Protein | Pharmacology | Lymphatic leukemia | Gene expression | Patients | Survival | Polymerase chain reaction | Cyclophosphamide | Chemotherapy | Fludarabine | Genotyping | Alleles | Biomarkers | Pretreatment | Pharmacokinetics
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 01/2012, Volume 118, Issue 2, pp. 434 - 443
BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced promising results in chronic lymphocytic leukemia and other... 
fludarabine | cyclophosphamide | purine analogs | Waldenstrom macroglobulinemia | and rituximab | immunochemotherapy
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 8, pp. 1455 - 1459
Journal Article
Annals of Hematology, ISSN 0939-5555, 9/2012, Volume 91, Issue 9, pp. 1459 - 1469
Recently, a less toxic regimen comprising reduced cyclophosphamide (Cy), fludarabine, and anti-thymocyte globulin (ATG) (Cy-Flu-ATG) was used to condition... 
Cyclophosphamide | Fludarabine | Medicine & Public Health | Hematology | Aplastic anemia | Oncology | Transplantation | Conditioning | Myelodysplastic syndrome | VENOOCCLUSIVE DISEASE | BONE-MARROW-TRANSPLANTATION | ANTITHYMOCYTE GLOBULIN | DONORS | CONDITIONING REGIMEN | LIVER | HEPATOTOXICITY | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Antibiotic Prophylaxis | Antilymphocyte Serum - administration & dosage | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Young Adult | Antilymphocyte Serum - therapeutic use | Adult | Female | Transplantation Conditioning - methods | Myelodysplastic Syndromes - surgery | Immunosuppressive Agents - administration & dosage | Myelodysplastic Syndromes - drug therapy | Antiviral Agents - therapeutic use | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Anemia, Aplastic - surgery | Adolescent | Anemia, Aplastic - drug therapy | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Histocompatibility | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 18, pp. 2779 - 2785
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal... 
Internal Medicine | CYTOKINE-RELEASE | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | PROGRESSION-FREE SURVIVAL | INITIAL THERAPY | LYMPHOMA | STEM-CELL TRANSPLANTATION | EXPRESSION | III TRIAL | DELETION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Incidence | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Severity of Illness Index | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Patient outcomes | Dosage and administration | Research | Drug therapy | Studies | Clinical trials | Mutation | Medical statistics | Epidemiology | Annual meetings | Teaching hospitals
Journal Article